Acute Labetalol Use in Preeclampsia



Status:Recruiting
Conditions:Women's Studies
Therapuetic Areas:Reproductive
Healthy:No
Age Range:18 - Any
Updated:3/15/2019
Start Date:February 18, 2019
End Date:July 1, 2021
Contact:Asha Rijhsinghani
Email:rijhsia@amc.edu
Phone:518.262.4942

Use our guide to learn which trials are right for you!

Acute Labetalol Use in Preeclampsia Randomized Trial

The purpose of this study is to understand if administration of a personalized dose of the
anti-hypertensive medication, labetalol, based on patient's body-mass index, will be more
effective at controlling severe hypertension during pregnancy, compared to the current
standard dosing.

The investigators seek to asses the effect of obesity (BMI>30) on severe hypertension control
in patients with preeclampsia with severe features. The investigators hypothesize that
successive administration of 40-60-80 mg of labetolol will reduce time to blood pressure
control versus the standard dosing, 20-40-80 mg labetolol, recommended by the American
College of Obstetricians and Gynecologists in 2015.

Inclusion Criteria:

- BMI ≥ 30

- Age ≥ 18 years

- Gestational age ≥ 24 weeks

- Singleton gestation

- One sustained severe range blood pressure at Albany Medical Center

Exclusion Criteria:

- Known allergic reaction to labetlol

- Persistent mild-moderate asthma (≥ 2 rescue inhaler uses per week in the previous
month)

- Obstructive airway disease

- Bradycardia < 70 beats/min

- Heart block > 1st degree or history of heart failure
We found this trial at
1
site
Albany, New York 12208
Phone: 518-262-4942
?
mi
from
Albany, NY
Click here to add this to my saved trials